Anixa Biosciences, Inc.

Day range

$2.89 – $2.98

Open

$2.94

Prev close

$2.99

Volume

106.46K

Market cap

$103.94M

Shares out

34.76M

P/E

—

P/S

—

P/B

7.18

P/FCF

—

ROE

-71.7%

ROA

-68.9%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsMar 11, 2026

  On March 10, 2026, Anixa Biosciences, Inc. (the "Company") completed its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders (i) re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors, (ii) approved, on a non-binding, advisory basis, the Company's executive compensation, and (iii) ratified the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2026.

• Regulatory decisionFeb 9, 2026

  regulatory approval had been granted enabling dose escalation in the trial beyond the doses set forth in the original trial protocol.

• Clinical trial resultsDec 12, 2025

  the Company and The Cleveland Clinic Foundation presented final data from the Phase 1 clinical trial of its investigational breast cancer vaccine.

• Annual meeting resultsMar 21, 2025

  On March 20, 2025, Anixa Biosciences, Inc. (the "Company") completed its 2025 annual meeting of stockholders (the "Annual Meeting")... At the Annual Meeting, the Company's stockholders (i) re-elected Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. as directors, (ii) approved, on a non-binding, advisory basis, the Company's executive compensation, (iii) ratified the appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2025 and (iv) selected, on a non-binding, advisory basis, one year as the frequency of conducting future stockholder advisory votes on named executive officer compensation.

• Clinical trial resultsNov 8, 2024

  the Company and The Cleveland Clinic Foundation presented new, updated positive data for the Phase 1 study of its breast cancer vaccine

Days to cover

3.7

Short interest

1.35M

Avg volume

366.18K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
  positiveBenzinga· Apr 29, 2026
• Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
  positiveBenzinga· Mar 9, 2026
• Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
  positiveBenzinga· Sep 16, 2025
• Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
  positiveBenzinga· Oct 31, 2024
• EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy - Benzinga
  positiveBenzinga· Jul 23, 2024